These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 25043171)

  • 1. The future of JAK inhibition in myelofibrosis and beyond.
    Mascarenhas JO; Cross NC; Mesa RA
    Blood Rev; 2014 Sep; 28(5):189-96. PubMed ID: 25043171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is there a role for JAK inhibitors in BCR-ABL1-negative myeloproliferative neoplasms other than myelofibrosis?
    Pardanani A; Tefferi A
    Leuk Lymphoma; 2014 Dec; 55(12):2706-11. PubMed ID: 25520049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 'JAK-ing' up the treatment of primary myelofibrosis: building better combination strategies.
    Assi R; Verstovsek S; Daver N
    Curr Opin Hematol; 2017 Mar; 24(2):115-124. PubMed ID: 28072602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis.
    Arana Yi C; Tam CS; Verstovsek S
    Future Oncol; 2015; 11(5):719-33. PubMed ID: 25757677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Novel therapeutics in myeloproliferative neoplasms: beyond JAK inhibitors].
    Edahiro Y
    Rinsho Ketsueki; 2023; 64(9):970-980. PubMed ID: 37793873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging targeted therapies in myelofibrosis.
    Barosi G
    Expert Rev Hematol; 2012 Jun; 5(3):313-24. PubMed ID: 22780211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic stem cell transplant vs.Janus kinase inhibition in the treatment of primary myelofibrosis or myelofibrosis after essential thrombocythemia or polycythemia vera.
    Alchalby H; Kröger N
    Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S36-41. PubMed ID: 25486953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.
    Kleppe M; Kwak M; Koppikar P; Riester M; Keller M; Bastian L; Hricik T; Bhagwat N; McKenney AS; Papalexi E; Abdel-Wahab O; Rampal R; Marubayashi S; Chen JJ; Romanet V; Fridman JS; Bromberg J; Teruya-Feldstein J; Murakami M; Radimerski T; Michor F; Fan R; Levine RL
    Cancer Discov; 2015 Mar; 5(3):316-31. PubMed ID: 25572172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Janus kinase inhibitors for the treatment of myeloproliferative neoplasms.
    Rosenthal A; Mesa RA
    Expert Opin Pharmacother; 2014 Jun; 15(9):1265-76. PubMed ID: 24766055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
    Roskoski R
    Pharmacol Res; 2016 Sep; 111():784-803. PubMed ID: 27473820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug Development Pipeline for Myeloproliferative Neoplasms: Potential Future Impact on Guidelines and Management.
    Bose P; Verstovsek S
    J Natl Compr Canc Netw; 2016 Dec; 14(12):1613-1624. PubMed ID: 27956543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging drug profile: JAK inhibitors.
    Coltoff A; Kuykendall A
    Leuk Lymphoma; 2024 Sep; 65(9):1258-1269. PubMed ID: 38739701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel therapeutics in myeloproliferative neoplasms.
    Venugopal S; Mascarenhas J
    J Hematol Oncol; 2020 Dec; 13(1):162. PubMed ID: 33267911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances with janus kinase inhibitors for the treatment of myeloproliferative neoplasms: an update of the literature.
    Hunter AM; Bose P
    Expert Opin Pharmacother; 2024 Jul; 25(10):1391-1404. PubMed ID: 39067001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations.
    Pardanani A; Vannucchi AM; Passamonti F; Cervantes F; Barbui T; Tefferi A
    Leukemia; 2011 Feb; 25(2):218-25. PubMed ID: 21079613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinase signaling and targeted therapy for primary myelofibrosis.
    Yang Q; Crispino JD; Wen QJ
    Exp Hematol; 2017 Apr; 48():32-38. PubMed ID: 28043820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reducing symptom burden in patients with myeloproliferative neoplasms in the era of Janus kinase inhibitors.
    Mesa RA; Scherber RM; Geyer HL
    Leuk Lymphoma; 2015 Jul; 56(7):1989-99. PubMed ID: 25644746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing efficacy in myelofibrosis treatment: a focus on JAK inhibition.
    Komrokji R; Verstovsek S
    Expert Rev Hematol; 2012 Dec; 5(6):631-41. PubMed ID: 23216593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of JAK inhibitors for low-risk myelofibrosis.
    Alimam S; McLornan D; Harrison C
    Expert Rev Hematol; 2015 Oct; 8(5):551-3. PubMed ID: 26343888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How we manage JAK inhibition in allogeneic transplantation for myelofibrosis.
    Ballinger TJ; Savani BN; Gupta V; Kroger N; Mohty M
    Eur J Haematol; 2015 Feb; 94(2):115-9. PubMed ID: 25256963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.